Abbvie (ABBV) PT Raised to $160 at Piper Sandler, Remains Top Pick in 2022
Tweet Send to a Friend
Piper Sandler analyst Christopher Raymond raised the price target on Abbvie (NYSE: ABBV) to $160.00 (from $129.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
